- Home
- FDMT vs AGMB Comparison
FDMT vs AGMB Comparison
Compare FDMT & AGMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FDMT | AGMB |
|---|---|---|
| Founded | 2013 | 2017 |
| Country | United States | Belgium |
| Employees | N/A | 62 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 479.9M | 562.4M |
| IPO Year | 2019 | N/A |
Fundamental Metrics
Financial Performance| Metric | FDMT | AGMB |
|---|---|---|
| Price | $10.42 | $11.82 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 3 |
| Target Price | $31.71 | ★ $32.00 |
| AVG Volume (30 Days) | ★ 646.0K | 121.4K |
| Earning Date | 05-08-2026 | 04-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 18.79 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $85,209,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $70.28 | $17.86 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 230194.60 | N/A |
| 52 Week Low | $3.03 | $9.00 |
| 52 Week High | $12.34 | $17.45 |
Technical Indicators
Market Signals| Indicator | FDMT | AGMB |
|---|---|---|
| Relative Strength Index (RSI) | 57.81 | 53.68 |
| Support Level | $9.71 | $9.62 |
| Resistance Level | $10.70 | $12.29 |
| Average True Range (ATR) | 0.59 | 1.03 |
| MACD | 0.10 | 0.20 |
| Stochastic Oscillator | 66.93 | 50.85 |
Price Performance
Historical ComparisonAbout FDMT 4D Molecular Therapeutics Inc.
4D Molecular Therapeutics Inc is biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. Companies focus is on advancing 4D-150 for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) through late-stage studies. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-710 and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector).
About AGMB AgomAb Therapeutics NV American Depositary Shares
AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need. Its product candidates are designed to target established pathways and utilize validated modalities, with a focus on addressing limitations associated with prior treatment approaches. The company's pipeline includes small molecule and antibody product candidates aimed at targets associated with fibrotic diseases. Key candidates include Ontunisertib (AGMB-129) and AGMB-447.